SeraCare posts Q4 loss after bioservice revenue halves

By Nick Taylor

- Last updated on GMT

SeraCare slipped into the red in the fourth quarter as loss of government business halved bioservice revenues.

A 46 per cent year-on-year fall in fourth quarter bioservice revenues contributed to SeraCare ending 2011 with a loss. Full year bioservice sales dropped by one-third to $11.3m (€8.4m) but SeraCare has a recovery strategy for 2012.

We do believe we have stabilised the revenue base for our bioservices business. Moving into fiscal 2012 we will focus on building the commercial side of our bioservices business which delivers higher gross margins​”, Greg Gould, interim CEO of SeraCare, said in a conference call with investors.

SeraCare may invest to return to growth. Gould said SeraCare has $18.1m in cash, minimal debt and is willing to use its funds to support future growth. This is one of five reasons SeraCare is optimistic about its future.

Joseph Nemmers, chairman of the board​at SeraCare, said: “We believe 2012 will be recognised as the year when SeraCare established itself as a growth oriented organisation​.” Growth will be driven by a revamped sales team, one-third of which is new to the company, and addition of new clients.

Strategic alternatives

Fiscal 2012 could also be the year SeraCare changes ownership. In August Gould told Outsourcing-Pharma SeraCare was looking into strategic alternatives and this “could mean a sale of the whole company, or it could mean a partial sale, or it could mean something else entirely​”.

SeraCare has advanced talks since then. “While the board’s pleased with progress we’re not ready to make public the details of this strategic process at this time. When we have something material to report we’ll let you know promptly​”, Nemmers said.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars